Aptose Biosciences Inc. Issues Press Release on February 13, 2025

Aptose Biosciences Inc., a leading biotechnology company, recently released a press statement on February 13, 2025. The company’s announcement pertains to a press release issued on the mentioned date, outlined in Exhibit 99.1 of its Form 8-K filing.

As per General Instruction B.2 of Form 8-K, the content covered in the press release, dated February 13, 2025, is not to be considered as part of a “filed” document under Section 18 of the Securities Exchange Act of 1934. Additionally, this information is not to be integrated by reference in any filings under the Securities Act of 1933 or the Exchange Act except as expressly stipulated by specific reference in such filings.

The press release provides vital information on Aptose Biosciences Inc.’s recent developments, strategies, or future prospects. Interested individuals and investors can refer to the detailed press release attached to Exhibit 99.1 of the Form 8-K filing for further insights.

This Form 8-K filing also includes Exhibit 104, which consists of a Cover Page Interactive Data File embedded within the Inline XBRL document.

Authorized by William G. Rice, Ph.D., President, and Chief Executive Officer, the report was officially signed and submitted on behalf of Aptose Biosciences Inc., meeting the requirements of the Securities Exchange Act of 1934.

For more detailed financial statements and specific exhibits, interested parties can refer to the official Form 8-K filing available through the Securities and Exchange Commission’s database.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Aptose Biosciences’s 8K filing here.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.